News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rainbow BioSciences, LLC: Short R&D Timeline Could Lead to Larger Profits


11/19/2012 9:42:40 AM

NOKOMIS, Fla.--(BUSINESS WIRE)--As Rainbow Coral Corp. looks ahead to a successful 2013, the company has placed a high priority on initiating projects that will realize profits quickly. The first project to be fast-tracked will be the company’s joint venture with Amarantus BioSciences (OTCBB: AMBS). Both companies forswear realizing revenues from the impending commercialization of Amarantus’ NuroPro, a sophisticated test developed to more accurately and easily diagnose Parkinson’s disease. NuroPro works by identifying differentiated levels proteins and peptides in the blood of patients who have the disease. RBCC and Amarantus expect to finalize NuroPro’s development timeline within the next 12-14 months. By cutting the typical timeline from years to only one year, RBCC and its shareholders believe they will see larger profits more quickly from the deal.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES